From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics
Walenczyk K, Singh A, Tong K, Burg M, Miller E. From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics. American Journal Of Health-System Pharmacy 2024, 81: 1245-1251. PMID: 38963826, DOI: 10.1093/ajhp/zxae183.Peer-Reviewed Original ResearchPatient sociodemographic characteristicsATTR-CASociodemographic characteristicsSpecialty pharmacyPyrophosphate scintigraphyPopulation prevalence ratesEconomically disadvantaged areasTransthyretin cardiac amyloidosisBlack/African American raceReduce disparitiesPotential patient subgroupsPharmacy processesProportion of daysClinical pathwayCompare sociodemographicsDisadvantaged areasEquitable provisionTafamidis therapyCardiac amyloidosisTafamidis treatmentPrevalence ratesClinical programsAmerican racePatient subgroupsPosting manuscripts
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply